Initiate Phase 1/2a clinical trial for OCU400

Deadline passed; outcome being checked

What the company said

“initiation of Phase 1/2a within a year”

SourceOcugen, Inc. Form 8-K press release, 2021-01-05
FilingSEC filing index
Deadline as statedwithin a year
Deadline used5 Jan 2022, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-OCGN-021091
Cite as https://keptindex.org/c/KI-C-2021-OCGN-021091/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 5 Jan 2021

Deadline 5 Jan 2022 (“within a year”)
Version 2 · stated 5 Feb 2021

Deadline 31 Dec 2021 (“this year”)

“OCU400 (AAV-NR2E3): 4 FDA Orphan Drug Designations with the potential to treat broad Retinitis Pigmentosa (RP)... initiation of Phase 1/2a this year”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Ocugen, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.